Research & Development

Our research efforts are focused on developing novel diagnostic technologies that are accurate, reliable, and accessible. From biomarker discovery to algorithm development, we're constantly pushing the boundaries of what's possible.

Collaboration

We believe in the power of collaboration. By partnering with leading institutions, industry experts, and healthcare professionals, we're able to leverage collective expertise and resources to accelerate the pace of innovation.

Identification of Needs

We start by identifying critical unmet needs in diagnostic medicine. Through collaboration with healthcare profesionals, patient advocacy groups, and industry experts, we gain insights into the challenges faced in rare disease detection and diagnosis.

Biomarker Discovery

Biomarkers are essential indicators of disease presence, progression, or response to treatment. Our team conducts extensive research to identify and validate biomarkers associated with specific diseases or conditions. This involves utilizing cutting-edge techniques such as molecular biology, genomics, and proteomics to uncover unique signals that can serve as diagnostic tools.

Technology Development

Once potential biomarkers are identified, we focus on developing and supporting innovative technologies for their detection and analysis. This may involve 

the design and optimization of assays, sensors, imaging modalities, or other diagnostic platforms tailored to the unique characteristics of the biomarkers and target rare diseases.

Algorithm Development

In parallel with technology development, we invest in the creation of sophisticated algorithms and computational models to interpret diagnostic data accurately. 

Machine learning, artificial intelligence, and data analytics play crucial roles in refining diagnostic algorithms to enhance sensitivity, specificity, and predictive accuracy.

Validation Studies

Rigorous validation studies are conducted to assess the performance and reliability of diagnostic tools across diverse patient populations and clinical settings. 

This phase involves collaboration with clinical partners and regulatory agencies to ensure compliance with rigorous standards of accuracy, precision, and reproducibility.